Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more
Beijing Hotgen Biotech Co Ltd (688068) - Total Liabilities
Latest total liabilities as of September 2025: CN¥278.25 Million CNY
Based on the latest financial reports, Beijing Hotgen Biotech Co Ltd (688068) has total liabilities worth CN¥278.25 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Beijing Hotgen Biotech Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Beijing Hotgen Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Beijing Hotgen Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing Hotgen Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Proximus PLC
PINK:BGAOF
|
USA | $8.38 Billion |
|
Gemadept Corp
VN:GMD
|
Vietnam | ₫4.92 Trillion |
|
Renishaw plc
PINK:RNSHF
|
USA | $199.53 Million |
|
Aarti Industries Limited
NSE:AARTIIND
|
India | ₹59.90 Billion |
|
Integrated Cannabis Company Inc
PINK:CRPGF
|
USA | $174.81 Billion |
|
Eyebright Medical Technology Beijing Co Ltd
SHG:688050
|
China | CN¥894.96 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Beijing Hotgen Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Hotgen Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Hotgen Biotech Co Ltd (2016–2024)
The table below shows the annual total liabilities of Beijing Hotgen Biotech Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥251.77 Million | +24.29% |
| 2023-12-31 | CN¥202.56 Million | -62.87% |
| 2022-12-31 | CN¥545.59 Million | -29.24% |
| 2021-12-31 | CN¥771.01 Million | +395.12% |
| 2020-12-31 | CN¥155.72 Million | +103.89% |
| 2019-12-31 | CN¥76.37 Million | +34.75% |
| 2018-12-31 | CN¥56.68 Million | +102.42% |
| 2017-12-31 | CN¥28.00 Million | -3.91% |
| 2016-12-31 | CN¥29.14 Million | -- |